Madrigal Pharmaceuticals Faces Securities Investigation After Whistleblower Suit Disclosures

Corporate Logo

Kaplan Fox & Kilsheimer LLP has launched a Madrigal Pharmaceuticals securities investigation into potential violations tied to newly disclosed litigation. The inquiry, announced November 9, 2026, focuses on the company’s recent public filing that revealed a former employee’s whistleblower retaliation complaint.

What the Filing Revealed

Article image

On November 3, 2026, before the market opened, Madrigal filed its Form 10-Q with the Securities and Exchange Commission. The filing disclosed that on October 9, 2026, a former employee filed a complaint in the United States District Court for the Northern District of Illinois. The case, Charlton v. Madrigal Pharmaceuticals, Inc., alleges retaliation under the whistleblower-protection provisions of the Sarbanes-Oxley Act of 2002, 18 U.S.C. § 1514A.

According to Madrigal’s disclosure, the plaintiff raised internal concerns about certain company data and reporting practices before resigning in January 2026. The complaint seeks monetary damages and other relief. Madrigal stated that it disputes the allegations and intends to defend itself vigorously.

Market Reaction

Corporate Logo

Following the disclosure, Madrigal’s stock price fell from a closing price of $431.16 per share on November 2, 2026, to close at $396.32 per share on November 3, 2026. That represents a decline of $34.84 per share, or 8.08%.

Investor Outreach

Kaplan Fox is encouraging Madrigal investors who have suffered losses, or who have information that could assist the investigation, to contact the firm. The firm can be reached by email at jcampisi@kaplanfox.com or by phone at (212) 329-8571.

About Kaplan Fox

Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide. The firm reports recovering more than $10 billion for clients and the classes it has represented.

Kaplan Fox has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. It has served as lead or co-lead counsel in several landmark cases, including a $2.425 billion recovery for Bank of America shareholders in In re Bank of America—the largest recovery ever obtained under Section 14(a) of the Securities Exchange Act—an $800 million recovery for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.

The firm notes that contacting or submitting information to Kaplan Fox does not create an attorney-client relationship, nor an obligation on the part of the firm to retain you as a client. Past results do not guarantee future outcomes.

Leave a comment

Your email address will not be published. Required fields are marked *